Prelude Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Current Ratio Growth & History (PRLD)
Prelude Therapeutics's current ratio was 1.99 for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.99 | −3.31 | −62.37% |
| 2024 | 2024-12-31 | 5.30 | −5.49 | −50.89% |
| 2023 | 2023-12-31 | 10.79 | 1.37 | +14.60% |
| 2022 | 2022-12-31 | 9.42 | −5.95 | −38.73% |
| 2021 | 2021-12-31 | 15.37 | −4.04 | −20.82% |
| 2020 | 2020-12-31 | 19.41 | 15.23 | +364.08% |
| 2019 | 2019-12-31 | 4.18 | — | — |
Prelude Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.07 | 0.39 | +10.74% |
| Q1 2026 | 2026-03-31 | 2.03 | −3.15 | −60.82% |
| Q4 2025 | 2025-12-31 | 1.99 | −3.31 | −62.37% |
| Q3 2025 | 2025-09-30 | 3.21 | −3.83 | −54.43% |
| Q2 2025 | 2025-06-30 | 3.68 | −4.15 | −53.04% |
| Q1 2025 | 2025-03-31 | 5.18 | −6.46 | −55.54% |
| Q4 2024 | 2024-12-31 | 5.30 | −5.49 | −50.89% |
| Q3 2024 | 2024-09-30 | 7.04 | −6.87 | −49.40% |
| Q2 2024 | 2024-06-30 | 7.83 | −9.30 | −54.29% |
| Q1 2024 | 2024-03-31 | 11.64 | 2.73 | +30.59% |
| Q4 2023 | 2023-12-31 | 10.79 | 1.37 | +14.60% |
| Q3 2023 | 2023-09-30 | 13.91 | 3.38 | +32.14% |
| Q2 2023 | 2023-06-30 | 17.13 | 1.41 | +8.94% |
| Q1 2023 | 2023-03-31 | 8.91 | −7.89 | −46.94% |
| Q4 2022 | 2022-12-31 | 9.42 | −5.95 | −38.73% |
| Q3 2022 | 2022-09-30 | 10.52 | −6.05 | −36.50% |
| Q2 2022 | 2022-06-30 | 15.72 | −7.75 | −33.02% |
| Q1 2022 | 2022-03-31 | 16.80 | −12.58 | −42.82% |
| Q4 2021 | 2021-12-31 | 15.37 | −4.04 | −20.82% |
| Q3 2021 | 2021-09-30 | 16.57 | −4.38 | −20.92% |
| Q2 2021 | 2021-06-30 | 23.48 | — | — |
| Q1 2021 | 2021-03-31 | 29.38 | — | — |
| Q4 2020 | 2020-12-31 | 19.41 | 15.23 | +364.08% |
| Q3 2020 | 2020-09-30 | 20.96 | — | — |
| Q4 2019 | 2019-12-31 | 4.18 | — | — |
Prelude Therapeutics current ratio trends
Over the last five fiscal years, Prelude Therapeutics's current ratio decreased from 19.41 to 1.99, a change of −17.42. The latest reported quarter, Q2 2026, shows 4.07.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...